Zafgen will soon enter a Phase 3 trial for its obesity drug beloranib and expects to have a rich year for data in 2015, said the company's CEO Dr. Tom Hughes. Hughes said the upcoming trial will focus on the effects of beloranib on patients with Prader-Willi Syndrome, a rare genetic condition. Next year Hughes is planning trials focusing on patients with diabetes. He said beloranib works differently from drugs developed by competitors like Vivus because it does not alter brain chemistry. Finally, Hughes said the company has more than enough cash to reach its goal, expecting to have $95 million by the end of 2014.
Scroll to Continue